---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-051072"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:51:00.201430+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Beam prices $500M underwritten offering of common stock and pre-funded warrants

## Summary
- Underwritten offering of 16,151,686 shares at $28.48 per share and pre-funded warrants for 1,404,988 shares at $28.47 each.
- Gross proceeds ~$500.0M; net proceeds after discounts and expenses ~$469.7M.
- Use of proceeds: platform technology, R&D for BEAM-101, BEAM-302 pivotal trial, ESCAPE conditioning trial, general corporate.
- Closing expected March 11, 2025; J.P. Morgan, Jefferies, Cantor, Citigroup, Wells Fargo as joint bookrunners.
- Pre-funded warrants exercisable immediately at $0.01 per share, with cashless exercise and beneficial ownership limitation.

## SEC filing metadata
- accession: 0001193125-25-051072
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000119312525051072/0001193125-25-051072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000119312525051072/d930164d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-051072
- JSON: https://secwatch.observer/filing/0001193125-25-051072.json
- Plain text: https://secwatch.observer/filing/0001193125-25-051072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.